Company profile: Aquinox Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of small molecule therapeutics for cancer and inflammatory diseases, including AQX-MN100 and a SH2-containing inositol 5'-phosphatase inhibition program; and of online pharmacy services offering over 1,700 prescription and over-the-counter drugs and a wide range of generics (Sildenafil, Finasteride, Dapoxetine, Ivermectin) with delivery across the US.
Products and services
- Generic Medications: Aquinox Pharmaceuticals offers a wide range of generic small-molecule medications, including Sildenafil, Finasteride, Dapoxetine, and Ivermectin, delivering affordable alternatives to brand-name drugs for targeted therapeutic needs
- Online Pharmacy Services: Aquinox Pharmaceuticals operates a nationwide-scale online pharmacy that delivers medications across the US, offering convenience and accessibility to customers
- Prescription and OTC Drugs: The company delivers a catalog-scale selection of over 1,700 prescription and over-the-counter drugs, ensuring a broad range for various health needs and access to necessary medications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Aquinox Pharmaceuticals
Perspective Therapeutics
HQ: United States
Website
- Description: Provider of radiopharmaceutical cancer theranostics and targeted alpha-particle radiotherapy, including Pb-203 diagnostics and Pb-212 treatment via targeting peptides. Offers clinical programs VMT-α-NET for neuroendocrine tumors and VMT01 for metastatic melanoma, and a proprietary Pb-212 isotope generator to secure key isotopes for clinical trials and commercial operations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Perspective Therapeutics company profile →
NBE Therapeutics
HQ: Switzerland
Website
- Description: Provider of oncology therapies based on proprietary antibody-drug conjugates, including SMAC-Technology enzymatic conjugation for site-specific ADC manufacturing, Transpo-mAb mammalian cell display antibody discovery, a PNU-159682 anthracycline toxin payload platform, immune-oncology ADCs that activate CD8 cytotoxic T cells, and the ROR1-targeting NBE-002 candidate.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NBE Therapeutics company profile →
Bolt Biotherapeutics
HQ: United States
Website
- Description: Provider of a biotechnology platform for cancer immunotherapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bolt Biotherapeutics company profile →
NanoSmart Pharmaceuticals
HQ: United States
Website
- Description: Provider of platform drug delivery technologies for solid-tumor cancers, including a human-derived Anti-Nuclear Antibody targeting necrotic tumor tissue, ANA-conjugated lipid nanoparticles for direct API delivery to tumor sites, and a thermally sensitive nanoemulsion enabling stable storage and release at body temperature, plus licensing and partnerships to enhance existing cancer drugs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NanoSmart Pharmaceuticals company profile →
ElsaLys Biotech
HQ: France
Website
- Description: Provider of therapeutic monoclonal antibody development, based in Lyon and Illkirch Graffenstaden, France.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ElsaLys Biotech company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Aquinox Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Aquinox Pharmaceuticals
2.2 - Growth funds investing in similar companies to Aquinox Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Aquinox Pharmaceuticals
4.2 - Public trading comparable groups for Aquinox Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →